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Background: HIV and tuberculosis (TB) are leading infectious diseases, with a high
risk of co-infection. The risk of TB in people living with HIV (PLHIV) is high soon after
sero-conversion and increases as the CD4 counts are depleted.
Methodology: We used routinely collected data fromCare and Treatment Clinics (CTCs)
in three regions in northern Tanzania. All PLHIV attending CTCs between January 2012 to
December 2017 were included in the analysis. TB incidence was defined as cases started
on anti-TBmedications divided by the person-years of follow-up. Poisson regression with
frailty models were used to determine incidence rate ratios (IRR) and 95% confidence
intervals (95% CI) for predictors of TB incidences among HIV positive patients.
Results: Among 78,748 PLHIV, 405 patients developed TB over 195,296 person-years
of follow-up, giving an overall TB incidence rate of 2.08 per 1,000 person-years. There
was an increased risk of TB incidence, 3.35 per 1,000 person-years, in hospitals
compared to lower level health facilities. Compared to CD4 counts of <350 cells/µl,
a high CD4 count was associated with lower TB incidence, 81% lower for a CD4 count
of 350–500 cells/µl (IRR 0.19, 95% CI 0.04–0.08) and 85% lower for those with a CD4
count above 500 cells/µl (IRR 0.15, 95% CI 0.04–0.64). Independently, those taking
ART had 66% lower TB incidences (IRR 0.34, 95% CI 0.15–0.79) compared to those
not taking ART. Poor nutritional status and CTC enrollment between 2008 and 2012
were associated with higher TB incidences IRR 9.27 (95% CI 2.15–39.95) and IRR 2.97
(95% CI 1.05–8.43), respectively.
Discussion: There has been a decline in TB incidence since 2012, with exception of
the year 2017 whereby there was higher TB incidence probably due to better diagnosis
of TB following a national initiative. Among HIV positive patients attending CTCs, poor
nutritional status, low CD4 counts and not taking ART treatment were associated with
higher TB incidence, highlighting the need to get PLHIV on treatment early, and the need
for close monitoring of CD4 counts. Data from routinely collected and available health
services can be used to provide evidence of the epidemiological risk of TB.
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INTRODUCTION
Tuberculosis (TB) is a disease caused by Mycobacteria
tuberculosis, which can be latent in humans for a long time
without clinical symptoms. Active TB can present as Pulmonary
Tuberculosis (PTB) or Extra-Pulmonary Tuberculosis (EPTB),
with cardinal features of fever, productive cough, hemoptysis,
and weight loss, though the presentation among HIV infected
individuals is often atypical. Several factors have been associated
with an increased risk of TB incidence, such as poverty,
malnutrition, and overcrowding, but the risk of active TB is
16–27 times higher in people living with HIV (PLHIV) compared
to those who are HIV negative (1). This is due to the impaired
and lowered innate and passive immunity against TB among
PLHIV (2), increasing the risk of getting a new TB infection
(3) and of progression from latent TB to active TB (3). New TB
infections, rather than reactivation, account for 88% of new TB
cases among PLHIV (4).
The risk of TB for PLHIV is high soon after sero-conversion
(5), and continues to increase with depletion of CD4 count (6).
The CD4 count is a diagnostic and/or prognostic marker that
normally measures the number of CD4 expressing T-cells (also
known as T helper cells). But the risk of TB among PLHIV
decreases after starting anti-retroviral therapy (ART) (53).
TB incidence has been falling since 2013, by 2% globally and
by 4% in Africa. However, in 2017, 10 million (range 9–11.1
million) new cases of TB were reported worldwide, of which
25% occurred in Africa and 87% in 30 high TB burden countries
(Tanzania included) (7). Of the cases, 90% were >15 years of age,
64% were males and 9% were HIV positive (7). The reported
cases include only 51% of the estimated 920,000 new TB cases
among PLHIV. Of the 1.5 million people enrolled at Care and
Treatment Clinics (CTCs) in 2017, 8% were diagnosed with TB
in the same year. Africa accounted for 72% of all HIV associated
TB cases in 2017 (7). The End TB Strategy has set a reduction
target of 80% in TB incidence (new cases per 100,000 population
per year), compared to the level in 2015 (7). Tanzania is one of
the High TB Burden Countries, and one of the High TB/HIV
Burden Countries. In Tanzania, it is estimated that of 154,000
(range 73,000–266,000) new cases of TB in 2017, 31% (48,000
[31,000–69,000]) were also HIV positive (7). But with only 93%
of TB patients in Tanzania having test results for HIV, of which
36% were co-infected with HIV, the true burden of TB among
HIV positive people could be underestimated. TB has been the
leading cause of death among HIV positive individuals (7), so a
close monitoring of its occurrence in this subgroup of people is
extremely important.
Several factors have been associated with TB incidence among
HIV positive individuals including limited functional status,
very low CD4 count (<50 cells/µl) (53), anemia, inappropriate
vaccinations, cigarette smoking, households with a family size of
3 to 4 people, a lower social class, non-adherence to drugs and
severe immunosuppression (8).
Several interventions have been implemented to try to reduce
the incidence of TB in Tanzania’s general population and among
HIV positive individuals. As some patients may present with
subclinical TB (9), WHO recommended active TB screening
(intensified case finding) for all PLHIV, and infection control
(10). In 2010, a gradual implementation of Genexpert MTB/RIF
for the early diagnosis of TB among all TB suspects started,
and was scaled up in 2013 (11). This test was initially only for
HIV positive patients or for those with recurring TB. In 2011,
the country introduced Isoniaziad Preventive Therapy (IPT)
among PLHIV (12), which appears to be effective at reducing
TB incidence (13). Recently, WHO is recommending a “test and
treat” policy which requires all individuals being diagnosed as
HIV positive to be put on ARVs immediately (14). Data from
CTCs in Northern Tanzania provides an opportunity to track the
incidence of TB among HIV patients through this spectrum of
different intervention programs.
It is important to study TB incidence rates among PLHIV
in Tanzania and compare it with the estimated global TB
incidence rate that has been calculated by WHO (7). This
can guide clinicians and policy makers on interventions and
practices to improve health outcomes, and help to develop
preventive measures to reduce the magnitude of the problem.
This study determined the predictors and TB incidences among
HIV positive patients since enrolment at Care and Treatment
Centers (CTCs) after a follow up period of 6 years (January 2012
to December 2017), in the Northern part of Tanzania. Hence
providing a big picture of the effects of several interventions that
have been implemented over the years.
METHODOLOGY
Study Design and Settings
This was a retrospective cohort study which included data
which have been routinely collected from patients attending
CTCs from 1st January 2012 to 31st December 2017 in the
Arusha, Kilimanjaro and Tanga regions. Both public and private
CTCs were included, categorized as hospitals (at district level
and above), health centers and dispensaries. At every visit,
all HIV patients attending a CTC have a regular check-up,
and a screening for opportunistic infections. The screening for
TB follows WHO recommendations through the assessment
of symptoms and signs. All these positive on the screening
symptoms (either showing a productive cough, persistent low
grade fever, night sweats, or weight loss) have to undergo
further testing. This can be done using Genexpert MTB/RIF, or
sputummicroscopy at centers that have no Genexpert MTB/RIF.
Genexpert MTB/RIF is a molecular diagnostic tool used for
diagnosis ofM. tuberculosis (MTB) and Resistance of these strains
to Rifampicin (RIF). Sputum from the patient is mixed with
Genexpert MTB/RIF buffer solution and is shaken and incubated
for 5–10min, before being pipetted into cartridge of Genexpert
MTB/RIF for computer assisted diagnosis. Those diagnosed with
TB are given anti-TB medication.
Study Population and Data Definitions
All patients (above 15 years of age) who were HIV positive
and attended one of 489 CTCs in the regions of Arusha,
Kilimanjaro, and Tanga during the period of 1st January 2012
to 31st December 2017 were included in this study. Those who
already had a TB diagnosis and/or were on TB treatment at the
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time of their first visit to the CTC were excluded, whilst those
treated for TB before the start of the study duration were not
excluded. The start time was taken to be 1st January 2012, or
the date of first enrollment at the CTC if enrollment was after
1st January 2012. End time was defined as whichever came first
among the following; the date there were last seen at a CTC,
the date of death, the date of the first TB incidence, or 31st
December 2017. A TB diagnosis was defined as being started
on anti-TB medications after being screened for TB during a
visit to a CTC, regardless of the method used to confirm a
TB diagnosis. The following predictor variables were collected;
age, sex, marital status, geographical location, baseline weight,
baseline HIV WHO clinical stage, use of ARV, use of IPT,
functional status, ARV adherence status, CTC enrollment year,
type of ARV regimen, and baseline CD4 counts.
Data Analysis
Data were de-identified and analyzed using a statistical software
package, STATA 15. After data cleaning, categorical data
were summarized as frequencies and percentages. Continuous
variables were summarized using their median and interquartile
range (IQR) or by using their mean and standard deviation.
Incidence rates, and 95% confidence intervals (95%CI), for
each level of independent variable were determined, as the
number of newly diagnosed TB cases over the person-years
at risk. Health facilities were used as a cluster variable, and
Analysis of Variance (ANOVA) was used to compare aggregate
rates of TB incidences by: health facility levels, health facility
types (dispensaries, health centers, and hospitals), health facility
ownership (private and public ownership) and regions (Arusha,
Kilimanjaro, and Tanga). A Poisson regression model with frailty
to adjust for the clustering at health facilities was used to obtain
incidence rate ratios (IRR) for TB, and 95% CI for socio-
demographic and clinical characteristics of the patients. Crude
incidence rate ratios were then adjusted for other independent
factors for TB.
Ethical Clearance
Ethical clearance was obtained from Kilimanjaro Christian
Medical University College Research and Ethical Committee
(Ethical clearance certificate number 2286). Permission from
the Ministry of Health—Tanzania and NACP (National AIDS
Control Program) authority to conduct the study was obtained.
All patients’ privacy and confidentiality were strictly observed
throughout the study.
RESULTS
The study included 78,748 HIV-positive patients who were
followed up for 195,296 person-years, with 405 patients recorded
as having had a new episode of TB during the follow up, giving
an incidence of TB of 2.08 (95% CI 1.88–2.29) per 1,000 person-
years (Table 1). Looking at ages, the highest incidence rates for
TB, 2.45 per 1,000 person-years (95% CI 2.01–2.99), were in
patients aged 35–44 years of age. The TB incidence in males
(Incidence= 3.70 per 1,000 person-years, 95% CI 3.21–4.27) was
higher than in females (Incidence= 1.50 per 1,000 person-years,
TABLE 1 | Incidence rates for TB by socio-demographic characteristics at
enrolment into HIV services in 78,748 patients in three regions of Tanzania.
Characteristics Number of
PLHIV
Number of
TB cases
Person-years
(in 1,000)
Incidence rate
per 1,000
(95% CI)
Overall 78,748 405 195.1 2.08 (1.88–2.29)
Age
15–24 8,453 28 13 2.15 (1.48–3.11)
25–34 21,150 98 40 2.45 (2.01–2.99)
35–44 26,281 143 68.8 2.08 (1.77–2.45)
45–55 15,343 92 47.4 1.94 (1.58–2.38)
Above 55 7,521 44 26 1.70 (1.26–2.28)
Sex
Male 21,983 188 50.7 3.70 (3.21–4.27)
Female 56,764 217 144.4 1.50 (1.31–1.72)
Marital status
Cohabiting 1,013 4 2.6 1.51 (0.57–4.03)
Divorced 7,335 49 19 2.58 (1.95–3.41)
Married 39,151 191 100.5 1.90 (1.65–2.19)
Single 19,969 111 48.4 2.29 (1.90–2.76)
Widow/widower 5,670 26 15.2 1.71 (1.17–2.51)
Region
Arusha 12,348 45 19.3 2.30 (1.74–3.12)
Kilimanjaro 26,133 134 66 2.03 (1.71–2.41)
Tanga 40,267 226 109.9 2.06 (1.81–2.34)
Year of follow up
2012 44,673 65 30.3 2.15 (1.68–2.74)
2013 12,288 81 30.8 2.63 (2.12–3.27)
2014 12,117 68 34 2.00 (1.58–2.54)
2015 10,563 46 36.9 1.25 (0.93–1.67)
2016 8,728 56 38.2 1.47 (1.13–1.91)
2017 6,208 89 25.1 3.55 (2.88–4.37)
95% CI 1.31–1.72). Those who were divorced and those from
Arusha region had higher TB incidences with incidence of 2.58
(95% CI 1.95–3.41) and 2.30 (95% CI of 1.74–3.12) per 1,000
person-years, respectively, than others (Table 1).
HIV patients with markers of lower immunity or advanced
disease (HIV stage 3&4, CD4 < 350 cells/µl, lower weight and
poorer nutritional status) had higher TB incidence than others
(Table 2). Patients with a severely poor nutritional status had a
TB incidence rate of 47.74 per 1,000 person-years (95% CI 26.44–
86.21), while those with a moderately poor nutritional status
had a TB incidence rate of 9.53 per 1,000 person-years (95%
CI 7.12–12.77), and those with an adequate nutritional status
had a TB incidence rate of 1.73 per 1,000 person-years (95% CI
1.54–1.95) (Table 2). Higher TB incidence rates was found in
those who were bedridden (Incidence = 32.20 per 1,000 person-
years, 95% CI 24.89–41.65) and those who were ambulatory
(Incidence= 31.06 per 1,000 person-years, 95% CI 18.99–54.14),
compared to those who were working (Incidence=1.73 per 1,000
person-years, 95% CI 1.55–1.93) (Table 1).
Analysis of Variance (ANOVA) was used to compare
rates of TB incidences across the following cluster variables:
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TABLE 2 | Incidence rates for TB by clinical characteristics at enrolment into HIV
services in 78,748 patients in three regions of Tanzania.
Characteristics Number of
PLHIV
Number of
TB cases
Person-years
per 1,000
Incidence rate
per 1,000
(95% CI)
Body weight
Below 40 kg 5,276 68 7.7 8.88 (7.00–11.27)
40–60 kg 44,135 263 100.9 2.61 (2.31–2.94)
Above 60 kg 23,680 49 67.2 0.73 (0.55–0.96)
HIV WHO stage
Stage 1 17,347 18 28.4 0.63 (0.40–1.01)
Stage 2 17,390 28 37.2 0.75 (0.52–1.09)
Stage 3 30,505 223 91.5 2.44 (2.14–2.78)
Stage 4 11,165 127 31.9 3.98 (3.34–4.73)
CD4 categories
Below 350 7,808 42 12.6 3.33 (2.46–4.51)
350–500 2,561 6 6.5 0.93 (0.42–2.06)
Above 500 3,098 4 9 0.44 (0.17–1.19)
Use of IPT
No 78,504 405 193.7 2.09 (1.90–2.31)
Yes 244 0 1.5 0
Ever use ART
No 5,428 72 17.9 4.03 (3.20–5.08)
Yes 73,320 333 177.3 1.88 (1.69–2.09)
Functional status
Bedridden 2,647 58 1.8 32.20 (24.89–41.65)
Ambulatory 340 14 0.4 31.06 (18.99–54.14)
Working 74,921 327 189 1.73 (1.55–1.93)
CTC enroll year
2003–2007 12,897 69 59.7 1.16 (0.91–1.46)
2008–2012 32,057 131 83.5 1.57 (1.32–1.86)
2013–2017 33,794 205 51.9 3.95 (3.44–4.53)
Nutritional status
Ok 50,727 278 160.5 1.73 (1.54–1.95)
Moderate 3,603 45 4.7 9.53 (7.12–12.77)
Severe 218 11 0.2 47.74 (26.44–86.21)
ARV regimen
First line 57,802 293 173.5 1.69 (1.51–1.89)
Second line 745 15 5.1 2.95 (1.78–4.89)
Others 512 0 0.4 –
facility types (dispensaries, health centers and hospitals), facility
ownership (private and public ownership) and regions (Arusha,
Kilimanjaro, and Tanga). There was a significant increased risk of
TB incidence in hospitals (3.35 per 1,000 person-years) compared
to TB incidences in the health centers (1.28 per 1,000 person-
years) and dispensaries (1.36 per 1,000 person-years), p-value
0.0306. There were no statistically significant differences in TB
incidences for the cluster variables of facility ownership and
region (Table 3).
After performing a multilevel analysis and controlling for
health facilities as clusters, several factors were significantly
related to an increased TB incidence amongHIV positive patients
such as the year of enrollment at a CTC, those enrolled between
TABLE 3 | Comparison of cluster level’s TB rates per 1,000 person-years.
Cluster
variables
Number of
TB cases
Number of
cluster
variables
with at least
1 TB case
Mean/average
TB cases per
cluster
variable
Average TB
rates per
1,000
person-years
per cluster
variable
p-value
(ANOVA)
comparing
TB rates for
cluster
variables
Facility types
Dispensary 12 38 0.32 1.36 0.0306
Health
centers
131 70 1.87 1.28
Hospitals 262 32 8.19 3.35
Overall 405 140 2.89 1.77
Facility ownership
Private 50 34 1.47 2.03 0.6632
Public 355 106 3.35 1.69
Overall 405 140 2.89 1.77
Region
Arusha 45 39 1.15 1.86 0.6754
Kilimanjaro 134 43 3.12 1.35
Tanga 226 58 3.9 2.03
Overall 405 140 2.89 1.77
2008 and 2012 had an IRR of 1.51 (95% CI 1.12–2.03) while
those enrolled between 2013 and 2017 had an IRR of 4.05 (95%
CI 3.04–5.39). Moderate and severe nutritional status were also
significantly associated with TB incidence among HIV patients,
with an IRR of 6.94 (95% CI 4.92–9.80) and 28.05 (95% CI
15.09–52.16), respectively. The use of second line ARVs had an
IRR of 1.75 (95% CI 1.04–2.97). The study found that several
factors were protective against developing new TB among HIV
patients, including being female and having CD4 count between
350 cells/µl to 500 cells/µl both of which were protective by 58%,
with IRRs of 0.42 (95% CI 0.34–0.50) and 0.42 (95% CI 0.21–
0.87), respectively. Using ARVs was protective by 57%, IRR 0.43
(95%CI 0.33–0.55). CD4 counts above 500 cells/µl was protective
by 84%, IRR 0.16 (95% CI 0.07–0.42) and having a working
functional status, were even more protective, by 95%, IRR 0.05
(95% CI 0.04–0.07) (Table 4).
After adjusting for both health facility type clusters and
other important factors, only two factors were found to be
significantly positively-related to incidence of TB, which are
severe malnutrition, IRR 9.27 (95% CI 2.15–39.95), and being
enrolled at a CTC between the years 2008 and 2012, IRR 2.97
(95% CI 1.05–8.43), compared to being enrolled in the years
2003 to 2007. The following factors remained as significantly
protective against TB incidence among HIV patients after doing
multilevel analysis. Having CD4 counts above 350 cells/µl with
IRRs of 0.19 (95% CI 0.04–0.80) and 0.15 (95% CI 0.04–0.64)
for CD4 counts between 350 and 500 cells/µl and above 500
cells/µl, respectively. Use of ART was protective by 66%, IRR
0.34 (95% CI 0.15–0.79), while a working functional status was
protective against TB incidence by 85%, IRR 0.15 (95% CI 0.05–
0.47) (Table 4). In this multilevel model and controlling for
health facility types as variable clusters, the intercept variability
across facilities was 0.78 (95% CI 0.23–2.73), with standard error
(SE) of 0.5.
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TABLE 4 | Poisson regression with multilevel analysis of the determinants of TB incidence in Northern Tanzania.
Characteristics Survival status Crude hazard ratio (95%C) Adjusted hazard ratio (95%CI)
adjusting only for clusters
AHR (95% CI) adjusting for other
factors and for clustersevent
(TB) censored
Age
15–24 28 8,425 1 1 1
25–34 98 21,052 1.16 (0.75–1.74) 1.19 (0.78–1.81) 1.01 (0.28–3.70)
35–44 143 26,138 0.95 (0.63–1.42) 0.97 (0.65–1.46) 0.46 (0.12–1.75)
55–55 92 15,251 0.87 (0.57–1.33) 0.89 (0.58–1.36) 0.52 (0.13–2.11)
Above 55 44 7,477 0.75 (0.47–1.21) 0.78 (0.48–1.25) 0.60 (0.13–2.77)
Sex
Male 188 21,795 1 1 1
Female 217 56,547 0.43 (0.36–0.52) 0.42 (0.34–0.50) 0.89 (0.41–1.92)
CD4 categories
Below 350 42 7,766 1 1 1
350–500 6 2,555 0.41 (0.20–0.84) 0.42 (0.21–0.87) 0.19 (0.04–0.80)
Above 500 4 3,094 0.16 (0.06–0.40) 0.16 (0.07–0.42) 0.15 (0.04–0.64)
Ever use art
No 51 5,356 1 1 1
Yes 354 72,987 0.46 (0.36–59) 0.43 (0.33–0.55) 0.34 (0.15–0.79)
Functional status
Bedridden 58 2,589 1 1 1
Ambulatory 14 326 0.97 (0.56–1.71) 0.92 (0.52–1.63) 2.14 (0.23–19.94)
Working 327 74,594 0.05 (0.04–0.07) 0.05 (0.04–0.07) 0.15 (0.05-0.47)
CTC enroll year
2003–2007 45 12,828 1 1 1
2008–2012 155 31,926 1.37 (1.03–1.84) 1.51 (1.12–2.03) 2.97 (1.05–8.43)
2013–2017 205 33,589 3.50 (2.66–4.59) 4.05 (3.04–5.39) 2.55 (0.79–8.20)
Nutritional status
Ok 278 50,449 1 1 1
Moderate 45 3,558 5.53 (4.04–7.58) 6.94 (4.92–9.80) 0.93 (0.20–4.22)
Severe 11 207 27.95 (15.30–51.06) 28.05 (15.09–52.16) 9.27 (2.15–39.95)
DISCUSSION
In this population of PLHIV attending CTCs for the years 2012
to 2017, in Northern Tanzania, the incidence rate of TB was
2.08 per 1,000 person-years, which is higher than the general TB
incidence rate of 1.29 per 1,000 Tanzanian general population,
for the year 2016, as reported by the Tanzania National TB and
Leprosy Program (NTLP), but lower than theWHOTB incidence
estimation of 2.7 per 1,000 population, in the year 2017 (7). But
this number is within the estimated range of 1.5–4 new cases per
1,000 in most of the 30 high TB burden countries among the
general population. Our estimated incidence rate is lower than
other studies done in Tanzania, which showed an incidence of
TB among HIV patients to be in the range of 8–17 per 1,000
person-years (15), but this was between the years of 2008 to 2010
for patients who were not on ART and before the introduction
of IPT. Another study done in a major city in Tanzania, Dar es
Salaam, found the incidence rate to be 27 per 1,000 person-years
(13). The city is highly crowded, has a high TB diagnostic capacity
and according to NTLP has the highest TB case notification rate
in the country. In Nigeria, TB incidence was 5.7 per 1,000 person-
years, among HIV patients on ARVs for the period of 2004 to
2012 (16). Higher incidences were found in South Africa (17) and
Ethiopia (18) with TB incidences of 44 per 1,000 person-years
and 86 per 1,000 person-years, respectively. According to WHO
incidence rates need to be falling by 4–5% per year up to 2020, in
order to reach the End TB Strategy milestone.
A study in Nigeria (16) and another in South Africa (17),
found males to have higher TB incidence than females. Age
is also associated with TB incidence with patients aged 25–
34 years having the highest incidence, while those aged 15–
24 years having the lowest incidence trend (Figure 1). This
agrees with other studies performed in Ethiopia (18) and Nigeria
(16). Age and sex differences in TB incidence could be due
to cultural factors and economical reasons, whereby men and
those in the most economically productive age group are less
likely to have time to attend clinics and to receive appropriate
care, including Isoniazid Preventive Therapy, hence are more
likely to be diagnosed with TB (Figure 2). Other studies have
shown that males have an increased TB prevalence than females
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FIGURE 1 | Cumulative hazard estimates (TB incidences) for age categories.
FIGURE 2 | Cumulative hazard estimates (TB incidences) for sex.
(especially in low- and middle-income countries) due to the fact
that men are disadvantaged in seeking and/or accessing TB care
in many settings (19). The same pattern has also been observed
in Europe (20).
The three regions of Arusha, Kilimanjaro, and Tanga had
essentially similar TB incidence rates, and there were no
significant differences between public and private facilities. All
health facilities in this dataset had at least one TB case, and
PLHIV seen at the hospitals for care and treatment had higher
TB occurrence than those attending lower level facilities. This
may be due to the fact that many lower level facilities have
poor or inadequate availability of diagnostic equipment, and have
low skilled health care workers. Hence leading to a reduced
capacity for diagnosing TB as these co-infected patients tend to
present with atypical TB manifestations which are difficult to
diagnose. However, this could also have been due to the referral
mechanisms, whereby most PLHIV with more advanced HIV
and probably with active TB tend to be referred to hospitals for
advanced care and treatment. In addition, most of these lower
level facilities do not hospitalize their patients. This observation
FIGURE 3 | Cumulative hazard estimates (TB incidences) for health facility
types.
was more pronounced in the later years of the study, after the
increased roll out of Genexpert MTB/RIF machines to many
higher level facilities (Figure 3).
Severe malnutrition was found to be associated with an
increased risk of TB among HIV patients in our study. Similar
findings have been observed in other settings, especially among
children (21) where malnutrition accounts for 26% of incident
TB (22). It is also positively associated with TB progression (23),
poor treatment outcomes (21) and delayed recovery (24). This is
because it deteriorates the cell mediated and humoral immunity
(21). Though most of the studies have focused on children,
malnutrition is common among adult TB patients (25), as well as
MDRTB patients (26) and in patients with other infections (27).
Strategies to manage malnutrition should incorporate routine
TB and HIV screening (28), and modifications to TB treatment
(29), though some studies have found that these additional
strategies are not yet effective (22) and that there is no significant
association between nutritional status and TB severity (30).
Even though this is controversial, but if implemented effectively,
these strategies might prevent TB incidence and increase the
probability of being cured (21, 31), and decrease the risk of TB
mortality especially among children (32).
Incident TB increased almost three times for those enrolled
in CTCs between 2008 and 2017 compared to those enrolled
between 2003 and 2007, the reason for which could be that most
of those enrolled between 2003 and 2007 were already on ARVs
for some time when we started following up in 2012. In general
TB incidence among HIV patients has been declining since 2012,
with the exception being during 2017. This decline is congruent
with the recent global and African data on TB epidemiological
burden, that there has been a consistent decline in TB over the
last decade, as well as in the most affected areas of Sub Saharan
Africa (7). Success can be attributed to an improved health
system; increased use of Isoniazid preventive therapy; increased
HIV prevention and awareness (33); early TB diagnosis (11) and
treatment; all of which reduces the risk of TB transmission, whilst
also strengthening the collaboration betweenHIV and TB control
activities when combined with other diseases. For the year 2017,
which had a higher incidence of 3.54 per 1,000 person-years
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(Table 1), this could be attributed to the increased roll out of
Genexpert MTB/RIF and that probability that most hospitals had
these molecular tests installed.
Our findings have shown that a CD4 count above 350 cells/µl,
or being on ARVs, was protective against the development of
incident TB. HIV increases TB risk through increasing the risk
of acquiring TB (3), or through reactivation of latent TB (2).
Immunity against other infections including TB is compromised
by HIV infection (34). The risk doubles after sero-conversion (5)
and remains high within the first 3 years after enrollment at CTCs
(18). TB risk is five times higher in the African region (1), and
especially for those with a history of previous TB disease (15),
and with a decreasing CD4 count (6), similar to our findings. As
found in other studies (35), the risk of TB incidence is there even
among HIV patients who are on IPT. The risk decreases with the
use of ARVs (33) as our study has found but can still remain 5
times higher compared toHIV uninfected persons (36) despite an
increase in their CD4 count. ART benefits are more pronounced
in preventing TB in patients with a lower CD4 count (37), this is
because ARVs in general restore immunity and so protect against
developing TB, but this is controversial as other studies have
found that ART use does not reduce TB incidence (38). Even so,
this ART protection seems to be lost when one is on second line
ARVs (39) as was also found in this study. Others have suggested
controlling for hemoglobin levels as low hemoglobin can be used
as a predictor of TB among these patients on ARVs (40).
Working functional status was significantly protective against
TB incidence as found in other studies (53). Other studies found
the risk factors for TB among HIV patients to be low hemoglobin
(40), increased HIV viral load (41), genetics (42), WHO HIV
stage 3, not taking Isoniazid (43), smoking, diabetes, alcohol use,
crowded living, poverty (44), variation in compliance to taking
ARTs (45), as well as social inequality in access to sanitation and
health expenditure per capita. Other studies have shown that the
following subpopulations have an increased risk of TB incidence:
prisoners (46), migrants (47), health care workers (48), miners
(4), and contacts of indexed TB cases (49). Other studies have
found that other protective factors against TB incidence include
the use of IPT (13, 50), cash transfers (51), as well as early TB
detection and treatment initiation (52).
This study’s strengths include the use of routinely collected
data from a large number of patients and the inclusion of
all health facilities providing electronic data for HIV care
and treatment across the three regions. It has also assessed
and adjusted for the differences between health facilities that
might affect TB incidence. The study was limited in that only
HIV positive patients who were identified to have a definitive
diagnosis of TB, or to have started TB medications, during follow
up were considered as TB incidence. The analysis has included
all new cases of TB, including those with no microbiological TB
confirmation. However, there could be an underestimation of
new TB cases among HIV patients if there were no diagnostic
tools available for presumptive TB cases (especially in lower
level health facilities), or if there was a delay or gap between
the diagnosis of TB and starting anti-TB medications. We
recommend future studies on determining the mechanisms
of nutritional effects on TB incidence and progression; the
association between second line ARVs and TB incidence; and
determining why the risk of TB remains higher even after
improving the CD4 count of HIV patients on ART. We also
recommend further analysis of the TB diagnosis cascade to see
how effective the system is for TB diagnosis.
CONCLUSION
Despite the prolonged decline of TB burden in most of the
African countries, in the last decade TB is still a public health
problem especially among HIV patients. Poor nutritional status
and being enrolled at the CTCs after 2007 were significantly
associated with TB incidence among HIV patients attending
CTCs since 2003 in Tanzania. So there needs to be effective
collaborative TB control strategies encompassing other diseases
including HIV, and a continuing improvement of health system
including the CTCs. Having a working functional status, a high
CD4 count (above 350 cells/µl), and using ART were protective
against TB incidence among HIV positive patients, though the
use of second line ARVs was found to be a risk factor for
developing TB. So all patients should be put on ARVs as soon
as possible, and close monitoring of all patients with a CD4 count
<350 cells/µl.
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